Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $43
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital has maintained its Buy rating on NRX Pharmaceuticals (NASDAQ:NRXP) but has lowered the price target from $50 to $43.
June 07, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ascendiant Capital has maintained its Buy rating on NRX Pharmaceuticals but has lowered the price target from $50 to $43.
The maintained Buy rating suggests continued confidence in NRX Pharmaceuticals' prospects, but the lowered price target indicates a tempered outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100